Successful ribavirin therapy for severe adenovirus hemorrhagic cystitis after allogeneic marrow transplant from close HLA donors rather than distant donors

K. Miyamura, M. Hamaguchi, H. Taji, T. Kanie, A. Kohno, M. Tanimoto, H. Saito, S. Kojima, T. Matsuyama, K. Kitaori, K. Nagafuji, T. Sato, Y. Kodera

Research output: Contribution to journalArticle

72 Citations (Scopus)

Abstract

Intravenous ribavirin was given to nine patients who had developed severe adenovirus-induced hemorrhagic cystitis (AD-HC) which was resistant to conventional therapy or where there was involvement of other organs after allogeneic BMT. Three patients recovered completely from AD-HC, two of whom had been resistant to vidarabine. All three had received sibling BMTs (2 HLA matched, 1 HLA mismatched). Five patients who received BMTs from related (2 HLA mismatched) or unrelated (1 HLA matched, 2 HLA mismatched) showed an improvement in symptoms but had recurrent AD-HC after discontinuation of ribavirin. Improvement in clinical symptoms and termination of virus excretion were well correlated. The last patient who received a mismatched unrelated BMT died during ribavirin therapy. Ribavirin was notably more effective among patients receiving BMTs from siblings in contrast to patients receiving BMTs from alternative donors (<0.05). One patient experienced severe pancytopenia during the second treatment with ribavirin after HC recurrence and recovered after ceasing ribavirin. Thus, ribavirin seems to be very effective for severe AD-HC for some recipients who receive transplants from a genetically close donor.

Original languageEnglish
Pages (from-to)545-548
Number of pages4
JournalBone Marrow Transplantation
Volume25
Issue number5
Publication statusPublished - 2000
Externally publishedYes

Fingerprint

Cystitis
Ribavirin
Adenoviridae
Bone Marrow
Tissue Donors
Transplants
Therapeutics
Siblings
Vidarabine
Pancytopenia
Viruses
Recurrence

Keywords

  • Adenovirus
  • BMT
  • Hemorrhagic cystitis
  • Ribavirin

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Successful ribavirin therapy for severe adenovirus hemorrhagic cystitis after allogeneic marrow transplant from close HLA donors rather than distant donors. / Miyamura, K.; Hamaguchi, M.; Taji, H.; Kanie, T.; Kohno, A.; Tanimoto, M.; Saito, H.; Kojima, S.; Matsuyama, T.; Kitaori, K.; Nagafuji, K.; Sato, T.; Kodera, Y.

In: Bone Marrow Transplantation, Vol. 25, No. 5, 2000, p. 545-548.

Research output: Contribution to journalArticle

Miyamura, K, Hamaguchi, M, Taji, H, Kanie, T, Kohno, A, Tanimoto, M, Saito, H, Kojima, S, Matsuyama, T, Kitaori, K, Nagafuji, K, Sato, T & Kodera, Y 2000, 'Successful ribavirin therapy for severe adenovirus hemorrhagic cystitis after allogeneic marrow transplant from close HLA donors rather than distant donors', Bone Marrow Transplantation, vol. 25, no. 5, pp. 545-548.
Miyamura, K. ; Hamaguchi, M. ; Taji, H. ; Kanie, T. ; Kohno, A. ; Tanimoto, M. ; Saito, H. ; Kojima, S. ; Matsuyama, T. ; Kitaori, K. ; Nagafuji, K. ; Sato, T. ; Kodera, Y. / Successful ribavirin therapy for severe adenovirus hemorrhagic cystitis after allogeneic marrow transplant from close HLA donors rather than distant donors. In: Bone Marrow Transplantation. 2000 ; Vol. 25, No. 5. pp. 545-548.
@article{4bebafee287744af9a2dcce5505f3e66,
title = "Successful ribavirin therapy for severe adenovirus hemorrhagic cystitis after allogeneic marrow transplant from close HLA donors rather than distant donors",
abstract = "Intravenous ribavirin was given to nine patients who had developed severe adenovirus-induced hemorrhagic cystitis (AD-HC) which was resistant to conventional therapy or where there was involvement of other organs after allogeneic BMT. Three patients recovered completely from AD-HC, two of whom had been resistant to vidarabine. All three had received sibling BMTs (2 HLA matched, 1 HLA mismatched). Five patients who received BMTs from related (2 HLA mismatched) or unrelated (1 HLA matched, 2 HLA mismatched) showed an improvement in symptoms but had recurrent AD-HC after discontinuation of ribavirin. Improvement in clinical symptoms and termination of virus excretion were well correlated. The last patient who received a mismatched unrelated BMT died during ribavirin therapy. Ribavirin was notably more effective among patients receiving BMTs from siblings in contrast to patients receiving BMTs from alternative donors (<0.05). One patient experienced severe pancytopenia during the second treatment with ribavirin after HC recurrence and recovered after ceasing ribavirin. Thus, ribavirin seems to be very effective for severe AD-HC for some recipients who receive transplants from a genetically close donor.",
keywords = "Adenovirus, BMT, Hemorrhagic cystitis, Ribavirin",
author = "K. Miyamura and M. Hamaguchi and H. Taji and T. Kanie and A. Kohno and M. Tanimoto and H. Saito and S. Kojima and T. Matsuyama and K. Kitaori and K. Nagafuji and T. Sato and Y. Kodera",
year = "2000",
language = "English",
volume = "25",
pages = "545--548",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - Successful ribavirin therapy for severe adenovirus hemorrhagic cystitis after allogeneic marrow transplant from close HLA donors rather than distant donors

AU - Miyamura, K.

AU - Hamaguchi, M.

AU - Taji, H.

AU - Kanie, T.

AU - Kohno, A.

AU - Tanimoto, M.

AU - Saito, H.

AU - Kojima, S.

AU - Matsuyama, T.

AU - Kitaori, K.

AU - Nagafuji, K.

AU - Sato, T.

AU - Kodera, Y.

PY - 2000

Y1 - 2000

N2 - Intravenous ribavirin was given to nine patients who had developed severe adenovirus-induced hemorrhagic cystitis (AD-HC) which was resistant to conventional therapy or where there was involvement of other organs after allogeneic BMT. Three patients recovered completely from AD-HC, two of whom had been resistant to vidarabine. All three had received sibling BMTs (2 HLA matched, 1 HLA mismatched). Five patients who received BMTs from related (2 HLA mismatched) or unrelated (1 HLA matched, 2 HLA mismatched) showed an improvement in symptoms but had recurrent AD-HC after discontinuation of ribavirin. Improvement in clinical symptoms and termination of virus excretion were well correlated. The last patient who received a mismatched unrelated BMT died during ribavirin therapy. Ribavirin was notably more effective among patients receiving BMTs from siblings in contrast to patients receiving BMTs from alternative donors (<0.05). One patient experienced severe pancytopenia during the second treatment with ribavirin after HC recurrence and recovered after ceasing ribavirin. Thus, ribavirin seems to be very effective for severe AD-HC for some recipients who receive transplants from a genetically close donor.

AB - Intravenous ribavirin was given to nine patients who had developed severe adenovirus-induced hemorrhagic cystitis (AD-HC) which was resistant to conventional therapy or where there was involvement of other organs after allogeneic BMT. Three patients recovered completely from AD-HC, two of whom had been resistant to vidarabine. All three had received sibling BMTs (2 HLA matched, 1 HLA mismatched). Five patients who received BMTs from related (2 HLA mismatched) or unrelated (1 HLA matched, 2 HLA mismatched) showed an improvement in symptoms but had recurrent AD-HC after discontinuation of ribavirin. Improvement in clinical symptoms and termination of virus excretion were well correlated. The last patient who received a mismatched unrelated BMT died during ribavirin therapy. Ribavirin was notably more effective among patients receiving BMTs from siblings in contrast to patients receiving BMTs from alternative donors (<0.05). One patient experienced severe pancytopenia during the second treatment with ribavirin after HC recurrence and recovered after ceasing ribavirin. Thus, ribavirin seems to be very effective for severe AD-HC for some recipients who receive transplants from a genetically close donor.

KW - Adenovirus

KW - BMT

KW - Hemorrhagic cystitis

KW - Ribavirin

UR - http://www.scopus.com/inward/record.url?scp=17044442190&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=17044442190&partnerID=8YFLogxK

M3 - Article

C2 - 10713633

AN - SCOPUS:17044442190

VL - 25

SP - 545

EP - 548

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 5

ER -